Since down-regulation of REST is responsible for signaling the NED of PCa, the development of β-TrCP specific inhibitors may provide a new strategy to increase the effectiveness of ADT treatment by prevention NED during ADT treatment. The gene discussed is BTRC; the disease is posterior cortical atrophy.